Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (38)
Shauli Minkowitz, Oluwatosin Ayeni, Mohamed Haffejee & Maureen Joffe. (2022) The effect of medical castration on lipid levels in black South African men with prostate cancer. African Journal of Urology 28:1.
Crossref
Crossref
Lennart J. van Winden & Huub H. van Rossum. 2022.
73
104
.
Muhammed Rashid, Madhan Ramesh, K. Shamshavali, Amit Dang, Himanshu Patel & Krishna Undela. (2020) Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials. Reviews on Recent Clinical Trials 15:1, pages 34-47.
Crossref
Crossref
Myles Brown, Laura Cato & Rinath Jeselsohn. 2019. Yen and Jaffe's Reproductive Endocrinology. Yen and Jaffe's Reproductive Endocrinology
717
741.e8
.
Panagiotis J. Vlachostergios, Marcia Paddock & Ana M. Molina. 2018. Precision Molecular Pathology of Prostate Cancer. Precision Molecular Pathology of Prostate Cancer
523
546
.
Masaki Shiota & Masatoshi Eto. (2016) Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. International Journal of Urology 23:5, pages 360-369.
Crossref
Crossref
Frank Kunath, Henrik R. Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich & Joerg J. Meerpohl. (2015) Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU International 116:1, pages 30-36.
Crossref
Crossref
Bobby C. Liaw, Jeffrey Shevach & William K. Oh. (2015) Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy. Current Urology Reports 16:3.
Crossref
Crossref
Tanya Barauskas Dorff & Jacek Pinski. 2015. Urological Oncology. Urological Oncology
817
833
.
Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich & Joerg J Meerpohl. (2014) Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Richard J. Santen, Linda R. Duska & Stephen H. Culp. 2014. Yen & Jaffe's Reproductive Endocrinology. Yen & Jaffe's Reproductive Endocrinology
651
698.e14
.
C. Bastide, F. Bruyère, G. Karsenty, L. Guy & F. Rozet. (2013) Le traitement hormonal du cancer de la prostate. Progrès en Urologie 23:15, pages 1246-1257.
Crossref
Crossref
Donald J. AbrahamRobert W. Brueggemeier. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
153
218
.
Takamitsu Inoue, Chikara Ohyama & Tomonori Habuchi. (2009) Hormonal therapy in prostate cancer. Drug Delivery System 24:4, pages 415-420.
Crossref
Crossref
Geert J. C. M. Kolvenbag & Barrington J.A. Furr. 2009. Hormone Therapy in Breast and Prostate Cancer. Hormone Therapy in Breast and Prostate Cancer
347
368
.
Mario A. Eisenberger. 2008. Prostate Cancer. Prostate Cancer
339
354
.
Grace Lu-Yao, Dirk F. Moore, John Oleynick, Robert S. DiPaola & Siu-Long Yao. (2006) Use of Hormonal Therapy in Men With Metastatic Prostate Cancer. Journal of Urology 176:2, pages 526-531.
Crossref
Crossref
Jane M. BlazebyKerry AveryMirjam SprangersHynek PikhartPeter FayersJenny Donovan. (2006) Health-Related Quality of Life Measurement in Randomized Clinical Trials in Surgical Oncology. Journal of Clinical Oncology 24:19, pages 3178-3186.
Crossref
Crossref
Laurence Collette, Tomasz Burzykowski, Kevin J. Carroll, Don Newling, Tom Morris & Fritz H. Schröder. (2005) Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Journal of Clinical Oncology 23:25, pages 6139-6148.
Crossref
Crossref
Ian D Cockshott. (2004) Bicalutamide. Clinical Pharmacokinetics 43:13, pages 855-878.
Crossref
Crossref
Thomas E. Hutson. 2004. Management of Prostate Cancer. Management of Prostate Cancer
561
578
.
Fabio EfficaceAndrew BottomleyDavid OsobaCarolyn GotayHenning FlechtnerSven D’haeseAlfredo Zurlo. (2003) Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?. Journal of Clinical Oncology 21:18, pages 3502-3511.
Crossref
Crossref
Fabio Efficace, Andrew Bottomley & George van Andel. (2003) Health related quality of life in prostate carcinoma patients. Cancer 97:2, pages 377-388.
Crossref
Crossref
Adam P Dicker. (2003) The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. The Lancet Oncology 4:1, pages 30-36.
Crossref
Crossref
Anna C. FerrariNelson StoneRichard StockMyron BednarIsaac EsseesseHarvinder SinghYvonne BaldwinJohn Mandeli. (2002)
13-
cis
Retinoic Acid and Complete Androgen Blockade in Advanced Hormone-Naive Prostate Cancer Patients: Report of a Phase II Randomized Study
. Journal of Clinical Oncology 20:2, pages 538-544.
Crossref
Crossref
Michael Naughton & Joel Picus. (2002) Advanced Prostate Cancer. American Journal of Cancer 1:1, pages 13-22.
Crossref
Crossref
Susan J. Bondy, Neill A. Iscoe, Deanna M. Rothwell, Elaine H. Gort, Neil E. Fleshner, Lawrence F. Paszat & George P. Browman. (2001) Trends in Hormonal Management of Prostate Cancer:. Medical Care 39:4, pages 384-396.
Crossref
Crossref
Donald L Trump, Joanne A Waldstreicher, Geert Kolvenbag, Paul S Wissel & Blake L Neubauer. (2001) Androgen antagonists: Potential role in prostate cancer prevention. Urology 57:4, pages 64-67.
Crossref
Crossref
G. J. C. M. Kolvenbag. (2001)
The Prostate Cancer Continuum: The Role of Bicalutamide (Casodex
®
)
. The Prostate Journal 3:1, pages 2-13.
Crossref
Crossref
P. Iversen, I. Melezinek & A. Schmidt. (2002) Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International 87:1, pages 47-56.
Crossref
Crossref
MENACHEM LAUFER, SAMUEL R. DENMEADE, VICTORIA J. SINIBALDI, MICHAEL A. CARDUCCI & MARIO A. EISENBERGER. (2000) COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. The Journal of Urology, pages 3-9.
Crossref
Crossref
MENACHEM LAUFER, SAMUEL R. DENMEADE, VICTORIA J. SINIBALDI, MICHAEL A. CARDUCCI & MARIO A. EISENBERGER. (2000) COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. Journal of Urology 164:1, pages 3-9.
Crossref
Crossref
Jerome SeidenfeldDavid J. SamsonVic HasselbladNaomi AronsonPeter C. AlbertsenCharles L. BennettTimothy J. Wilt. (2000) Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer. Annals of Internal Medicine 132:7, pages 566.
Crossref
Crossref
Francesco BoccardoAlessandra RubagottiMario BarichelloMichele BattagliaGiorgio CarmignaniGiancarlo ComeriGiario ContiGiorgio CrucianiSandro DamminoUmberto DellipontiPasquale DitonnoValentino FerrarisSergio LilliuFranco MontefioreFilippo PortogheseGiovanni Spano. (1999) Bicalutamide Monotherapy Versus Flutamide Plus Goserelin in Prostate Cancer Patients: Results of an Italian Prostate Cancer Project Study. Journal of Clinical Oncology 17:7, pages 2027-2027.
Crossref
Crossref
Geert J.C.M. Kolvenbag & Anthony Nash. (1999) Bicalutamide dosages used in the treatment of prostate cancer. The Prostate 39:1, pages 47-53.
Crossref
Crossref
A.J. Dowling & I.F. Tannock. (1998) Systemic treatment for prostate cancer. Cancer Treatment Reviews 24:4, pages 283-301.
Crossref
Crossref
Peter Iversen, Chris J. Tyrrell, Amir V. Kaisary, John B. Anderson, Luc Baert, Teuvo Tammela, Michael Chamberlain, Kevin Carroll, Karen Gotting-Smith & George R.P. Blackledge. (1998) Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51:3, pages 389-396.
Crossref
Crossref
Geert J.C.M. Kolvenbag, George R.P. Blackledge & Karen Gotting-Smith. (1998) Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development. The Prostate 34:1, pages 61-72.
Crossref
Crossref